Bridging the species divide: Transgenic mice humanized for type-I interferon response

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Harari, Daniel ^a   Abramovich, Renne ^a   Zozulya, Alla ^b   Smith, Paul ^b   Pouly, Sandrine ^b   Köster, Mario ^c   Hauser, Hansjörg ^c   Schreiber, Gideon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MERCK SERONO S A   (Switzerland)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BETA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS HYBRIDIZATION; CYTOKINE RESPONSE; DOSE RESPONSE; GENE; GENE ACTIVATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; MOUSE; MX2 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; CELL LINE; HOMOZYGOTE; HUMANS; INTERFERON TYPE I; LUCIFERASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TRANSFECTION; TRANSGENES;

EID: 84897487028     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084259     Document Type: Article

References (36)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975-990. doi:10.1038/nrd2422. (Pubitemid 350201788)
2. Moraga I, Harari D, Schreiber G, Uzé G, Pellegrini S (2009) Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol 29: 4778-4787. doi:10.1128/MCB.01808-08.
3. Levin D, Harari D, Schreiber G (2011) Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol 31: 3252-3266. doi:10.1128/MCB.05251-11.
4. Shen X, Hong F, Nguyen VA, Gao B (2000) IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 480: 132-136.
5. Radaeva S, Jaruga B, Kim W-H, Heller T, Liang TJ, et al. (2004) Interferongamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C. Biochem J 379: 199-208. doi:10.1042/BJ20031495. (Pubitemid 38491375)
6. Fenner JE, Starr R, Cornish AL, Zhang J-G, Metcalf D, et al. (2006) Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 7: 33-39. doi:10.1038/ni1287. (Pubitemid 41823866)
7. Zheng H, Qian J, Carbone CJ, Leu NA, Baker DP, et al. (2011) Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood 118: 4003-4006. doi:10.1182/blood-2011-06-359745.
8. Carbone CJ, Zheng H, Bhattacharya S, Lewis JR, Reiter AM, et al. (2012) Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies. Proc Natl Acad Sci U S A 109: 19226-19231. doi:10.1073/pnas.1211491109.
9. Francois-Newton V, Livingstone M, Payelle-Brogard B, Uzé G, Pellegrini S (2012) USP18 establishes the transcriptional and anti-proliferative interferon α/β differential. Biochem J 446: 509-516. doi:10.1042/BJ20120541.
10. Fuchs SY (2012) Ubiquitination-mediated regulation of interferon responses. Growth Factors Chur Switz 30: 141-148. doi:10.3109/08977194.2012. 669382.
11. Müller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921. (Pubitemid 24245635)
12. Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336. doi:10.1146/annurev.immunol.23.021704.115843. (Pubitemid 40563172)
13. Piehler J, Thomas C, Garcia KC, Schreiber G (2012) Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev 250: 317-334. doi:10.1111/imr.12001.
14. Apelbaum A, Yarden G, Warszawski S, Harari D, Schreiber G (2013) Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands. Mol Cell Biol 33: 800-814. doi:10.1128/MCB.01430-12.
15. Yong VW, Chabot S, Stuve O, Williams G (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51: 682-689. (Pubitemid 28449243)
16. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, Digioia G, et al. (2011) Binding and activity of all human alpha interferon subtypes. Cytokine 56: 282-289. doi:10.1016/j.cyto.2011.07.019.
17. Kalie E, Jaitin DA, Abramovich R, Schreiber G (2007) An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem 282: 11602-11611. doi:10.1074/jbc.M610115200. (Pubitemid 47100799)
18. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G (2008) The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 283: 32925-32936. doi:10.1074/jbc.M806019200.
19. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, et al. (2011) Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146: 621-632. doi:10.1016/j.cell.2011.06.048.
20. Roberts RM, Liu L, Guo Q, Leaman D, Bixby J (1998) The evolution of the type I interferons. J Interf Cytokine Res Off J Int Soc Interf Cytokine Res 18: 805-816. (Pubitemid 28489658)
21. Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421. (Pubitemid 24217131)
22. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ (2009) INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 37: D852-857. doi:10.1093/nar/gkn732.
23. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485. doi:10.1038/nature09907.
24. Staeheli P, Sutcliffe JG (1988) Identification of a second interferon-regulated murine Mx gene. Mol Cell Biol 8: 4524-4528.
25. Staeheli P, Haller O, Boll W, Lindenmann J, Weissmann C (1986) Mx protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 44: 147-158. (Pubitemid 16036722)
26. Pulverer JE, Rand U, Lienenklaus S, Kugel D, Zietara N, et al. (2010) Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol 84: 8626-8638. doi:10.1128/JVI.00303-10.
27. Kraus J, Oschmann P (2006) The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 11: 755-762. doi:10.1016/j.drudis. 2006.06.008.
28. Neuhaus O, Kieseier BC, Hartung H-P (2007) Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 259: 27-37. doi:10.1016/j.jns.2006.05.071. (Pubitemid 47031199)
29. Williams GJ, Witt PL (1998) Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interf Cytokine Res Off J Int Soc Interf Cytokine Res 18: 967-975. (Pubitemid 28565800)
30. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, et al. (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 297: 1059-1066. (Pubitemid 32472504)
31. Schlapschy M, Binder U, Börger C, Theobald I, Wachinger K, et al. (2013) PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel PEDS. doi:10.1093/protein/gzt023.
32. Chen J, Baig E, Fish EN (2004) Diversity and relatedness among the type I interferons. J Interf Cytokine Res Off J Int Soc Interf Cytokine Res 24: 687-698. doi:10.1089/jir.2004.24.687. (Pubitemid 39658232)
33. Kagan L, Abraham AK, Harrold JM, Mager DE (2010) Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 27: 920-932. doi:10.1007/s11095-010-0098-6.
34. Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, et al. (2004) Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 47: 4897-4904. doi:10.1021/jm0497693. (Pubitemid 39238265)
35. West GB, Brown JH, Enquist BJ (1997) A general model for the origin of allometric scaling laws in biology. Science 276: 122-126. (Pubitemid 27161259)
36. Kalincik T, Spelman T, Trojano M, Duquette P, Izquierdo G, et al. (2013) Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis. PloS One 8: e63480. doi:10.1371/journal.pone.0063480.